Skip to content

EBITDA margin at other companies

Eli Lilly logo
Eli LillyLLY
45.9%+14.4pp
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-46.5%-1.0pp
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-32%-10.7pp
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
-27.5%-12.2pp
ALN
Alnylam PharmaceuticalsALNY
18.8%+16.9pp
Beam Therapeutics logo
Beam TherapeuticsBEAM
-212.9%-85.3pp

Other financials

Income statement

See full
Revenue$38.2M+317%
Operating income-$31.3M+37.2%
Net income-$26.1M+44.4%
EPS (diluted)-$0.13+55.2%

Balance sheet

See full
Cash & equivalents$544.6M+124%
Total debt$15.7M-33.4%
Total equity$511.7M+198%
Total assets$583.5M+102%

Cash flow

See full
Operating cash flow-$59.6M+5.5%
CapEx$438.0K+165%
Free cash flow-$60.0M+5.1%

Valuation

See full
Market cap$1.14B+13.0%
Enterprise value$615.92M-22.3%
P/S15.1×-12.2×

Profitability

See full
Operating margin-75.7%-33.6pp
Net margin-66.5%-29.9pp
FCF margin-27.2%-12.6pp

Returns & leverage

See full
Return on equity-53.7%
Debt / equity-0.1×
Current ratio11.3×+8.3×

Where this comes from

Calculated from Wave Life Sciences’s reported figures.

Based on trailing twelve months.

The official record: Wave Life Sciences’s 10-Q, filed August 8, 2024, on SEC EDGAR. View the filing →

Ask your AI about Wave Life Sciences's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Wave Life Sciences's EBITDA margin?
Wave Life Sciences (WVE) reported EBITDA margin of -71.8% in Q2 2024.
How has Wave Life Sciences's EBITDA margin changed year-over-year?
Wave Life Sciences's EBITDA margin increased by 79.9% year-over-year, from -356.5% to -71.8%.
What is the long-term trend for Wave Life Sciences's EBITDA margin?
Over 3 years (2020 to 2023), Wave Life Sciences's EBITDA margin has grown at a -57.5% compound annual growth rate (CAGR), from -723.5% to -55.6%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.